Merck Terns Acquisition MASH CML — PatSnap Eureka
Merck–Terns Acquisition: TERN-501 THRβ Agonist and Resmetirom Competitive Positioning
Merck's acquisition of Terns Pharmaceuticals brings a Phase II THRβ agonist and an extensive combination-therapy patent portfolio into direct competition with FDA-approved resmetirom (Rezdiffra). Understand the IP landscape, mechanistic differentiation, and strategic rationale with PatSnap Eureka.
What Is TERN-501? The THRβ Agonist at the Heart of the Merck Acquisition
TERN-501 — chemically identified as 2-[[(3,5-dichloro-4-pyrrolidine-1-yl-phenyl)amino]methyl]-α-(methylsulfonyl)benzofuran-5-acetic acid (Compound A) — is a selective thyroid hormone receptor beta (THRβ) agonist developed by Terns Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Its distinct benzofuran scaffold differentiates it chemically from resmetirom, the first FDA-approved THRβ agonist for MASH.
By selectively activating the THRβ receptor in the liver, TERN-501 promotes hepatic fatty acid oxidation, reduces liver fat content, and exerts anti-fibrotic effects — without the systemic thyroid side effects historically associated with non-selective thyromimetics. The compound has been formulated as crystalline tablet forms, with Terns filing US20240108613A1 to protect its pharmaceutical formulation intellectual property.
Terns has also filed patents covering methods of treating liver disease by titrating the dose of TERN-501 during treatment (US20230218590; WO2024039758), recognising that dose optimisation is a critical clinical differentiator for life sciences assets in this class. Additionally, Terns has explored TERN-501's application in hepatocellular carcinoma (US20240342141) and hypothyroidism (US20240238290), expanding the asset's potential beyond MASH monotherapy.
The acquisition by patent-intensive pharma major Merck brings TERN-501 alongside CML (chronic myeloid leukaemia) assets from Terns' pipeline, reflecting Merck's strategy to diversify across both metabolic liver disease and oncology.
Resmetirom vs TERN-501: Positioning in the MASH THRβ Agonist Race
Resmetirom (Rezdiffra) is the only FDA-approved medication for non-cirrhotic MASH with significant fibrosis. TERN-501 enters a field that now also includes programmes from Gilead, Roche, and others.
Resmetirom (Rezdiffra) — First-in-Class, FDA Approved
Resmetirom is the only FDA-approved medication for non-cirrhotic MASH with significant fibrosis. Madrigal has filed solid oral dosage form patents (WO2024073310) and combination patents with GLP-1 receptor agonists (US20240293399, CN118179021) and for heterozygous familial hypercholesterolemia (WO2023150555), actively building a lifecycle management portfolio around the approved product.
FDA Approved · Non-cirrhotic MASHTERN-501 — Next-Generation Combination-Ready THRβ Agonist
TERN-501's distinct benzofuran scaffold and comprehensive combination therapy IP portfolio — covering GLP-1 agonists, FXR agonists, ACC inhibitors, PPAR agonists, SCD-1 inhibitors, SGLT2 inhibitors, and PCSK9 inhibitors — positions it as a mechanistically versatile combination partner. Terns also patented combination treatment with both a THRβ agonist and an additional therapeutic agent broadly (WO2024039800, US20240335421).
Phase II · 7 Combination Axes PatentedTHRβ Agonist Compounds + ACC Inhibitor Combinations
Gilead has filed THRβ agonist compound patents (WO2022225932, WO2022225935) and combination therapy patents pairing ACC inhibitors with THRβ agonists for NAFLD/NASH (WO2022235877). Gilead's IP analytics positioning reflects its broader metabolic disease pipeline strategy.
Preclinical–Phase I · ACC Combination FocusSelective THRβ Agonists for Hepatic Impairment & Steatosis
Roche has filed two WO2024 patent families covering selective THRβ agonists for treating hepatic impairment (WO2024121359) and hepatic steatosis (WO2024121362), as well as a broader chronic liver disease application (WO2024170685). Roche's entry signals continued big-pharma interest in the THRβ mechanistic class post-resmetirom approval.
Preclinical · Hepatic Impairment FocusTERN-501 and THRβ Agonist IP Data Visualised
PatSnap Eureka analysis of 526 THRβ agonist patent and literature results reveals Terns' dominant filing position and the breadth of its combination therapy strategy.
THRβ Agonist MASH Patent Filings by Assignee
Terns Pharmaceuticals leads the THRβ agonist patent landscape with 17 filings, nearly 3× the volume of nearest competitor Madrigal (6 filings), reflecting its combination therapy IP strategy ahead of Merck acquisition.
TERN-501 Combination Therapy Patent Portfolio — 7 Mechanistic Axes
Terns filed 7 distinct WO2024 combination therapy patent families in a single filing wave, covering every major metabolic and hepatic mechanistic partner class — a deliberate strategy to maximise TERN-501's combinability value for Merck.
TERN-501 vs Resmetirom: IP and Clinical Positioning Compared
A structured comparison of the two leading THRβ agonist assets across key differentiation dimensions, based on PatSnap Eureka patent data.
| Dimension | Resmetirom (Rezdiffra) | TERN-501 (Terns/Merck) |
|---|---|---|
| Regulatory Status | FDA Approved Non-cirrhotic MASH LEAD | Phase II MASH |
| Chemical Class | Selective THRβ agonist (Madrigal scaffold) | Selective THRβ agonist (benzofuran scaffold) DISTINCT |
| Formulation IP | Solid oral dosage forms patented (WO2024073310) | Crystalline forms & tablet formulations patented (US20240108613) |
| Combination Therapy IP | GLP-1 RA combination (US20240293399); HeFH (WO2023150555) | 7 patented axes: GLP-1 RA, FXR, ACC, PPAR, SCD-1, SGLT2, PCSK9 LEAD |
| Dose Titration IP | Dosing regimens in clinical trial patents | Dedicated titration method patents (US20230218590; WO2024039758) DISTINCT |
Need live MASH competitive intelligence?
PatSnap Eureka monitors THRβ agonist filings, trial updates, and M&A signals in real time.
Why the Merck–Terns Acquisition Matters for MASH Drug Development
Four strategic signals from the patent and clinical data that explain Merck's rationale and the implications for the broader MASH competitive landscape.
Combination-First IP Strategy
Terns filed 7 TERN-501 combination therapy patent families in a single coordinated wave in May 2024 — covering GLP-1 RA, FXR, ACC, PPAR, SCD-1, SGLT2, and PCSK9 partners. This breadth signals that Terns (and now Merck) views TERN-501's primary commercial value as a combination backbone, not a monotherapy. Resmetirom's combination portfolio is narrower, focused primarily on GLP-1 RA co-administration.
Differentiated Scaffold Reduces FTO Risk
TERN-501's benzofuran-based chemical scaffold (2-[[(3,5-dichloro-4-pyrrolidine-1-yl-phenyl)amino]methyl]-α-(methylsulfonyl)benzofuran-5-acetic acid) is structurally distinct from resmetirom. This differentiation, protected through Terns' core composition-of-matter patents (WO2022087022, US20230192683, US20240083873), provides Merck with a freedom-to-operate position independent of Madrigal's IP estate — a critical consideration for a late-stage development asset.
The Post-Resmetirom Approval Wave: New Entrants Accelerating
Resmetirom's FDA approval in 2024 as the first — and currently only — approved medication for non-cirrhotic MASH with significant fibrosis has triggered a significant acceleration in competitive THRβ agonist development. According to FDA guidance frameworks and ClinicalTrials.gov registrations, the MASH therapeutic area has become one of the most active in hepatology drug development.
Beyond the primary players, Inventiva has patented a combination of lanifibranor (a pan-PPAR agonist) and resmetirom for NASH treatment (US20240173307), demonstrating that third-party combination strategies are also emerging. Sichuan University has filed patents on THRβ agonist applications in metabolic syndrome (CN116602952, US20240100017), while Guangzhou University of Chinese Medicine has explored hyperlipidemia applications (CN115957205).
Protagonist Therapeutics has filed selective THRβ agonist patents for thyroid eye disease (WO2022125954), demonstrating the mechanistic class's utility beyond liver disease. The PatSnap customer base includes leading pharma and biotech teams tracking exactly these cross-indication expansion signals.
For R&D teams and IP professionals tracking the MASH space, PatSnap's IP analytics platform and PatSnap Eureka provide real-time monitoring of new THRβ agonist filings, clinical trial updates, and M&A signals across all jurisdictions. The NIH and EMA regulatory frameworks continue to shape endpoint requirements for MASH trials, making patent intelligence on clinical methodology IP increasingly valuable.
Merck–Terns Acquisition & MASH THRβ Agonists — key questions answered
TERN-501 (Compound A: 2-[[(3,5-dichloro-4-pyrrolidine-1-yl-phenyl)amino]methyl]-α-(methylsulfonyl)benzofuran-5-acetic acid) is a selective thyroid hormone receptor beta (THRβ) agonist developed by Terns Pharmaceuticals for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). By selectively activating the THRβ receptor in the liver, TERN-501 promotes hepatic fatty acid oxidation, reduces liver fat content, and exerts anti-fibrotic effects without the systemic thyroid side effects associated with non-selective thyromimetics.
Resmetirom (Rezdiffra, Madrigal Pharmaceuticals) is the only FDA-approved medication for non-cirrhotic MASH with significant fibrosis and represents the benchmark THRβ agonist in the class. TERN-501 is a next-generation THRβ agonist in Phase II development with a distinct chemical scaffold (benzofuran-based) and an extensive combination therapy patent portfolio covering GLP-1 receptor agonists, FXR agonists, ACC inhibitors, PPAR agonists, SGLT2 inhibitors, SCD-1 inhibitors, and PCSK9 inhibitors — positioning it as a combination-ready asset beyond resmetirom's current label.
Merck's acquisition of Terns Pharmaceuticals brings in the MASH-focused THRβ agonist TERN-501 (Phase II) alongside CML (chronic myeloid leukaemia) assets from Terns' pipeline. The acquisition reflects Merck's strategic intent to expand in metabolic liver disease — a high-value therapeutic area following resmetirom's FDA approval — and to access Terns' broad combination therapy intellectual property across multiple MASH mechanistic axes.
Terns Pharmaceuticals has filed a suite of WO2024 combination therapy patents pairing TERN-501 (Compound A, THRβ agonist) with: GLP-1 receptor agonists (WO2024097637), FXR agonists (WO2024097640), ACC inhibitors (WO2024097635), PPAR agonists (WO2024097636), SCD-1 inhibitors (WO2024097638), SGLT2 inhibitors (WO2024097641), and PCSK9 inhibitors (WO2024097639). This portfolio establishes TERN-501 as a mechanistically versatile combination partner across the MASH treatment landscape.
Beyond Terns Pharmaceuticals (TERN-501) and Madrigal Pharmaceuticals (resmetirom/Rezdiffra), active THRβ agonist programmes for MASH include Hoffmann-La Roche (selective THRβ agonists for hepatic impairment and hepatic steatosis, WO2024121359 and WO2024121362), Gilead Sciences (THRβ agonist compounds and ACC inhibitor combinations, WO2022225932 and WO2022235877), and Inventiva (lanifibranor plus resmetirom combination for NASH, US20240173307). The competitive field has expanded significantly since resmetirom's FDA approval in 2024.
Terns has filed patents specifically covering methods of treating liver disease by titrating the dose of a THRβ agonist during treatment (US20230218590, WO2024039758). Dose titration strategies are clinically important for THRβ agonists to balance hepatic efficacy against any systemic thyroid-axis signals during Phase II and Phase III development, and these patents protect Terns' (now Merck's) clinical dosing methodology as a competitive differentiator.
Still have questions about TERN-501, resmetirom, or the Merck–Terns deal? Let PatSnap Eureka answer them.
Ask PatSnap Eureka About MASH PatentsAccelerate Your MASH & THRβ Agonist Intelligence
Join 18,000+ innovators already using PatSnap Eureka to track drug pipelines, map competitive IP, and identify combination therapy opportunities across MASH and beyond.
References
- US20240108613A1 — Terns Pharmaceuticals: Thyroid hormone receptor beta agonist formulations (TERN-501 crystalline forms and tablet formulations)
- WO2022087022A1 — Terns Pharmaceuticals: Thyroid hormone receptor beta agonists and methods of use
- WO2024039800A1 — Terns Pharmaceuticals: Combination therapies with thyroid hormone receptor beta agonist
- US20230218590A1 — Terns Pharmaceuticals: Methods of treating liver disease with thyroid hormone receptor beta agonist therapy (dose titration)
- WO2024039758A1 — Terns Pharmaceuticals: Methods of treating liver disease with thyroid hormone receptor beta agonist therapy (dose titration)
- WO2024097637A1 — Terns Pharmaceuticals: Combination Treatment of MASH with THR-beta Agonist and GLP-1 Receptor Agonist
- WO2024097640A1 — Terns Pharmaceuticals: Combination Treatment of MASH with THR-beta Agonist and FXR Agonist
- WO2024097635A1 — Terns Pharmaceuticals: Combination Treatment of MASH with THR-beta Agonist and ACC Inhibitor
- WO2024097636A1 — Terns Pharmaceuticals: Combination Treatment of MASH with THR-beta Agonist and PPAR Agonist
- WO2024097638A1 — Terns Pharmaceuticals: Combination Treatment of MASH with THR-beta Agonist and SCD-1 Inhibitor
- WO2024097641A1 — Terns Pharmaceuticals: Combination Treatment of MASH with THR-beta Agonist and SGLT2 Inhibitor
- WO2024097639A1 — Terns Pharmaceuticals: Combination Treatment of MASH with THR-beta Agonist and PCSK9 Inhibitor
- US20240342141A1 — Terns Pharmaceuticals: Methods for Treating Hepatic Tumors (HCC) with TERN-501
- US20240238290A1 — Terns Pharmaceuticals: Methods for treating hypothyroidism with THRβ agonists
- WO2024073310A1 — Madrigal Pharmaceuticals: Solid oral dosage forms of thyroid hormone receptor beta agonists (resmetirom/Rezdiffra)
- WO2024081706A1 — Madrigal Pharmaceuticals: Resmetirom for treating MASH and hypercholesterolemia
- US20240293399A1 — Madrigal Pharmaceuticals: Combination of resmetirom and GLP-1 receptor agonist for treatment of MASH
- WO2023150555A1 — Madrigal Pharmaceuticals: Thyroid hormone receptor beta agonists for the treatment of heterozygous familial hypercholesterolemia
- WO2024121359A1 — Hoffmann-La Roche: Selective thyroid hormone receptor beta (THR-Beta) agonists for treating hepatic impairment
- WO2024121362A1 — Hoffmann-La Roche: Selective THR-Beta agonists for treating hepatic steatosis
- WO2022225932A1 — Gilead Sciences: Thyroid hormone receptor beta agonist compounds
- WO2022235877A1 — Gilead Sciences: Combinations of ACC inhibitors and thyroid hormone receptor-beta agonists for NAFLD/NASH
- US20240173307A1 — Inventiva: Treatment of non-alcoholic steatohepatitis with lanifibranor and resmetirom
- WO2022125954A1 — Protagonist Therapeutics: Selective thyroid hormone receptor beta agonists for treating thyroid eye disease
- U.S. Food and Drug Administration (FDA) — MASH drug approval and regulatory guidance
- ClinicalTrials.gov — THRβ agonist and MASH clinical trial registry
- National Institutes of Health (NIH) — MASH/NASH research and clinical endpoint frameworks
- European Medicines Agency (EMA) — MASH regulatory framework and guidance
All patent data and competitive intelligence on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform, based on analysis of 526 THRβ agonist MASH patent and literature results via PatSnap Eureka.
PatSnap Eureka searches patents and research to answer instantly.